Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
// Jhih-Pu Syu 1 , Jen-Tsan Chi 2, 3 , Hsiu-Ni Kung 1 1 Department of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taipei, Taiwan 2 Center for Genomic and Computational Biology, Duke University, Durham, NC, USA 3 Department of Molecular Genetics & Microbiology, Duke University, Durham, NC, USA Correspondence to: Hsiu-Ni Kung, e-mail: kunghsiuni@gmail.com Keywords: Nrf2, hypoxia, drug resistance, antioxidant activity, breast tumor Received: September 02, 2015 Accepted: January 29, 2016 Published: February 15, 2016 ABSTRACT Hypoxia leads to reactive oxygen species (ROS) imbalance, which is proposed to associate with drug resistance and oncogenesis. Inhibition of enzymes of antioxidant balancing system in tumor cells was shown to reduce chemoresistance under hypoxia. However, the underlying mechanism remains unknown. The key regulator of antioxidant balancing system is nuclear factor erythroid 2-related factor 2 (NFE2L2, Nrf2). In this study, we showed that hypoxia induced ROS production and increased the Nrf2 activity. Nrf2 activation increased levels of its downstream target antioxidant enzymes, including GCLC and GCLM. The Nrf2-overexpressing also confers chemo-resistant MCF7 cells under normoxia. The in vivo mouse model also demonstrated that the chemical inhibition of Nrf2 can increase cisplatin (CDDP) cytotoxicity. Together, these results showed that Nrf2 serves as a key regulator in chemotherapeutic resistance under hypoxia through ROS-Nrf2-GCLC-GSH pathway. Therefore, targeting Nrf2 can be a potential treatment for hypoxia-induced drug resistance in breast cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537 · cited 1×
“The cytotoxic effect of CDDP mainly resulted from the inhibition of DNA replication and the induction of apoptosis through the ROS pathway [29].”
BackgroundKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · cited 1×
“Hif-1α expression has been associated with the chemo-resistance of cancer cells by inhibiting apoptosis and induction of drug efflux [40, 41].”
BackgroundChandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melendez, J. A., Rodriguez, A. M., & Schumacker, P. T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001914200 · Cited by 2,000
The role of glutathione-S-transferase in anti-cancer drug resistance
Townsend, D. M., & Tew, K. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206940 · Cited by 1,353
Links between metabolism and cancer
Dang, C. V. (2012) · Genes & Development · doi:10.1101/gad.189365.112 · Cited by 1,100
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067
Teicher, B. A. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00689633 · Cited by 563
Redox activation of Nrf2 & NF-κB: A double end sword?
Buelna-Chontal, M., & Zazueta, C. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.08.007 · Cited by 239
Bell, E. L., Klimova, T. A., Eisenbart, J., Schumacker, P. T., & Chandel, N. S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02265-06 · Cited by 237 · cited 2×
“Previous studies have indicated hypoxia leads to intracellular oxidative imbalance [1].”
BackgroundHIF-1 Signaling in Drug Resistance to Chemotherapy
Warfel, N. A., & El-Deiry, W. S. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140414101056 · Cited by 109
Oxygen versus Reactive Oxygen in the Regulation of HIF-1α: The Balance Tips
Hagen, T. (2012) · Biochemistry Research International · doi:10.1155/2012/436981 · Cited by 100 · cited 1×
“Hypoxia-induced ROS, particularly that of H2O2, has been reported to be involved in the regulation of hypoxic responses [28].”
Background
Cited by
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
“At high concentrations (10–30 μm), ROS can damage cellular biomolecules, such as proteins, DNA, and RNA, and cause mutations that promote cancer in normal cells or multidrug resistance (MDR) in cancer cells [54].”
BackgroundModulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling
Luo, M., Shang, L., Brooks, M. D., Jiagge, E., Zhu, Y., Buschhaus, J. M., Conley, S., Fath, M. A., Davis, A., Gheordunescu, E., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.006 · Cited by 358
The Role of Nrf2 Activity in Cancer Development and Progression
Zimta, A.-A., Cenariu, D., Irimie, A., Magdo, L., Nabavi, S. M., Atanasov, A. G., & Berindan-Neagoe, I. (2019) · Cancers · doi:10.3390/cancers11111755 · Cited by 292
Metadata
- Authors
- Syu, J.-P., Chi, J.-T., & Kung, H.-N.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-02-15
- Volume
- 7
- Issue
- 12
- Pages
- 14659-14672
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2276797747
- Cited by
- 132
- References
- 11
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.